$4.10
-5.9%Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Last Annual Value
0.00
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Failed to load chart data
| Company | minority-interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
No comparison data available We couldn't find minority-interest data for this stock's competitors. | |||||
Continue your ZURA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.